<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Revenue Forecast on FinanClub</title>
    <link>https://finan.club/tags/revenue-forecast/</link>
    <description>Recent content in Revenue Forecast on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 12 Aug 2023 06:24:34 +0000</lastBuildDate><atom:link href="https://finan.club/tags/revenue-forecast/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>VFC</title>
      <link>https://finan.club/us/vfc/</link>
      <pubDate>Sat, 12 Aug 2023 06:24:34 +0000</pubDate>
      
      <guid>https://finan.club/us/vfc/</guid>
      <description>score:-191
Chances: V.F. Corporation (VFC) reported a daily gain of 3.78% with positive Earnings Per Share (EPS) results, indicating potential growth. VF Corporation beats earnings expectations, with reported EPS exceeding expectations in the first quarter of fiscal year 2024. Although V.F. (VFC) delivered lower-than-expected earnings and revenue surprises for the quarter ended June 2023, the company&amp;rsquo;s performance might be worth considering compared to the year-ago numbers.</description>
    </item>
    
    <item>
      <title> GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Tue, 08 Aug 2023 07:17:02 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:724
Chances: Gilead Sciences expects a third of sales to come from its cancer treatments by 2030, driving optimism and stock price movement. Gilead Sciences is focused on developing therapies for life-threatening infectious diseases and expanding its portfolio to include pulmonary, cardiovascular diseases, and cancer treatments.</description>
    </item>
    
  </channel>
</rss>
